New Delhi, Feb. 24 : The US-based Nostrum Pharmaceuticals has obtained worldwide licensing rights from the Indian-based Institute of Microbial Technology (IMTECH), to develop and commercialise Caerulomycin A, and its proprietary derivatives and analogues for their novel indication and immunosuppression.
IMTECH is a constituent laboratory of the Council of Scientific and Industrial Research (CSIR),
Significance of the deal lies in potential of Caerulomycin to develop into a blockbuster drug to be used to prevent organ transplantation rejection and diseases such as certain autoimmune disorders where immunosuppression is the key to the mitigation of the symptoms.
Hyderabad-based drug maker Aurobindo Pharmaceuticals has notified that it has received US regulatory approval for Tenofovir Disoproxil Fumarate tablets, used in the treatment of HIV infections in adults.
It should be noted that Tenofovir Disoproxil Fumarate tablet, is the generic equivalent of Gilead Science Inc's Viread Tablet 300mg and falls under the anti-retroviral segment.
The company has already obtained a license from Gilead to market Tenofovir products in 95 developing and least developed countries.
Prague - French pharmaceutical group Sanofi-Aventis is set to take control of the Czech generics maker Zentiva as smaller shareholders agreed to sell their stakes in the company.
Czech financial group J&T, which holds a 7.6 per cent stake in Zentiva through a subsidiary, said Friday it had accepted Sanofi- Aventis' buyout offer of 1,150 koruny (51 dollars) per share.
Glaxo Pharmaceuticals reported 157 per cent increase in net profit for the fourth quarter ended December 31, 2008 due to significant increase in its income during the reporting period.
The company posted net profit of Rs 208.4 crore against Rs 80.9 crore in the same period last year, despite recession like situation across the world. Its total income stood at Rs 1742.6 crore, posting increase of 5.31 per cent as compared to total income of Rs 1654.6 crore for the fourth quarter in 2007.
Glaxosmithkline Pharmaceuticals announced its quarterly results for the period ending December 31, 2008. It posted 157 per cent increase in net profit for the third quarter of current financial year.
The company has posted a net profit of Rs 208.4 crore for the fourth quarter, as against Rs 80.9 crore during the corresponding period last fiscal.
During the quarter, the company said that its income from operations rose to Rs 374.8 crore in December quarter, where as the same was at Rs 346.7 crore in the previous year.
MSD India, a wholly-owned subsidiary of US drug maker Merck & Co, has revealed its plans to hire 300 people by December end this year.
Hyderabad-based drug maker Aurobindo Pharmaceuticals has notified that it has received US regulatory approval for Tenofovir Disoproxil Fumarate tablets, used in the treatment of HIV infections in adults.
Prague - French pharmaceutical group Sanofi-Aventis is set to take control of the Czech generics maker Zentiva as smaller shareholders agreed to sell their stakes in the company.
Glaxo Pharmaceuticals reported 157 per cent increase in net profit for the fourth quarter ended December 31, 2008 due to significant increase in its income during the reporting period.
Glaxosmithkline Pharmaceuticals announced its quarterly results for the period ending December 31, 2008. It posted 157 per cent increase in net profit for the third quarter of current financial year. 
